Oncology Data Advisor

Recently, Ravi Parikh, MD, MPP, an Assistant Professor of Medical Ethics and Health Policy and Medicine at the University of Pennsylvania, Perelman School of Medicine, released a research letter titled, “Exposure to US Cancer Drugs With Lack of Confirmed Benefit After US Food and Drug Administration Accelerated Approval.” In this interview with OncData, he further discusses his research and gives a thought-provoking analysis of what these findings could mean for the future of the accelerated approval program, as well as how the multidisciplinary team could better advocate and let their voices be heard for more quality clinical trials.